Literature DB >> 34188250

Dual role of WNT5A in promoting endothelial differentiation of glioma stem cells and angiogenesis of glioma derived endothelial cells.

Taoliang Chen1, Fabing Zhang1, Jie Liu1, Zhilin Huang1, Yaofeng Zheng1, Shaokang Deng1, Yang Liu2, Jihui Wang3, Xinlin Sun4.   

Abstract

Glioma is a devastating cancer with a rich vascular network. No anti-angiogenic treatment is available for prolonging the overall survival of glioma patients. Recent studies have demonstrated that the endothelial differentiation of glioma stem cells (GSCs) into glioma-derived endothelial cells (GDECs) may be a novel target for anti-angiogenic therapy in glioma; however, the underlying mechanisms of this process remain unknown. Here, we report that wingless-related integration site (WNT) family member 5A (WNT5A) plays significant roles in GSC endothelial differentiation and GDECs angiogenesis. WNT5A is preferentially secreted by GDECs, and inhibition of WNT5A suppresses angiogenesis and tumorigenesis in GDECs. Silencing of WNT5A in GDECs also disrupts the impact of GDECs on stimulating GSC endothelial differentiation. Frizzled-4 is a receptor that mediates the effect of WNT5A on GSC endothelial differentiation and angiogenesis of GDECs via GSK3β/β-catenin/epithelial-mesenchymal transition signalling. The shWNT5A@cRGD-DDD liposomes, targeting WNT5A, exert anti-angiogenic effects in vivo. In this study, we identified that WNT5A has a dual functional role in modulating the endothelial differentiation of GSCs and angiogenesis of GDECs, indicating that WNT5A is a potential target for anti-angiogenesis-based therapeutics in glioma.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34188250     DOI: 10.1038/s41388-021-01922-2

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  48 in total

Review 1.  Malignant gliomas in adults.

Authors:  Patrick Y Wen; Santosh Kesari
Journal:  N Engl J Med       Date:  2008-07-31       Impact factor: 91.245

2.  Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.

Authors:  Yuji Piao; Ji Liang; Lindsay Holmes; Verlene Henry; Erik Sulman; John F de Groot
Journal:  Clin Cancer Res       Date:  2013-06-26       Impact factor: 12.531

3.  Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.

Authors:  Hai-Bo Wu; Shuai Yang; Hai-Yan Weng; Qian Chen; Xi-Long Zhao; Wen-Juan Fu; Qin Niu; Yi-Fang Ping; Ji Ming Wang; Xia Zhang; Xiao-Hong Yao; Xiu-Wu Bian
Journal:  Autophagy       Date:  2017-08-16       Impact factor: 16.016

4.  Glioblastoma stem-like cells give rise to tumour endothelium.

Authors:  Rong Wang; Kalyani Chadalavada; Jennifer Wilshire; Urszula Kowalik; Koos E Hovinga; Adam Geber; Boris Fligelman; Margaret Leversha; Cameron Brennan; Viviane Tabar
Journal:  Nature       Date:  2010-11-21       Impact factor: 49.962

Review 5.  Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis.

Authors:  Yulei Chen; Longbin Guo; Xuanzi Li; Rongping Liu; Chen Ren; Shasha Du
Journal:  Clin Neurol Neurosurg       Date:  2020-09-20       Impact factor: 1.876

Review 6.  The Glioma Stem Cell Model in the Era of Single-Cell Genomics.

Authors:  Mario L Suvà; Itay Tirosh
Journal:  Cancer Cell       Date:  2020-05-11       Impact factor: 31.743

7.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

8.  Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study.

Authors:  John M Mariadason; Niall C Tebbutt; Jennifer Mooi; Fiona Chionh; Peter Savas; Jessica Da Gama Duarte; Geoffrey Chong; Stephen Brown; Rachel Wong; Timothy J Price; Alysson Wann; Effie Skrinos
Journal:  Clin Cancer Res       Date:  2021-01-29       Impact factor: 12.531

9.  The necessity for standardization of glioma stem cell culture: a systematic review.

Authors:  Lei Zhang; Hongwei Yu; Yuhui Yuan; John S Yu; Zhenkun Lou; Yixue Xue; Yunhui Liu
Journal:  Stem Cell Res Ther       Date:  2020-02-26       Impact factor: 6.832

Review 10.  Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer.

Authors:  Ye Zeng; Bingmei M Fu
Journal:  Front Cell Dev Biol       Date:  2020-12-09
View more
  1 in total

1.  Diffuse Large B-Cell Lymphoma Promotes Endothelial-to-Mesenchymal Transition via WNT10A/Beta-Catenin/Snail Signaling.

Authors:  Xianting Sun; Jianchen Fang; Fen Ye; Shuxian Zhang; Honghui Huang; Jian Hou; Ting Wang
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.